The company
Ipsen Group
Ipsen is a dynamic and growing global specialty-driven biopharmaceutical company focused on innovation and specialty care. We aim to make a sustainable difference by significantly improving patients’ health and quality of life and providing them with effective therapeutic solutions for unmet medical needs through differentiated and innovative medicines in oncology, neurosciences and rare diseases. The patient is at the heart of everything we do, and we also care for our employees because they are the ambassadors who truly make the difference. We attract and develop bold, agile, entrepreneurial individuals who take full ownership of their decisions; leaders drawn by a purpose to make a direct impact through their work in people’s lives. We offer employees a wealth of fulfilling challenges & growth opportunities, and the chance to contribute within a fast-moving organisation, an organisation that is genuinely game-changing.
Ipsen is a global specialty-driven pharmaceutical company and also has a significant presence in consumer healthcare. Ipsen commercialize more than 20 drugs in over 115 countries, with a direct commercial presence in 30 countries worldwide. The Group has about 5,800 employees worldwide. The company recorded a net sale of 2,224.8 million Euros 2018 and a growth of 16.6% vs previous year.
Our strategy
Ipsen’s strategy is based on a focus on niche therapeutic areas in specialty care and on gastroenterology in consumer healthcare.
• Specialty care:
o A focus on three niche therapeutic areas where Ipsen is committed to continue being or becoming leader in high unmet need disease areas of oncology, neurology and rare disease;
o Ipsen continues to strengthen its presence in its historical therapeutic specialty areas such as uro-oncology, neurospastic disorders and endocrinology
o At the same time, we are pursuing advancements in othertherapeutic areas within oncology and rare disease.
• Consumer healthcare:
o Ipsen aims to optimize its gastroenterology portfolio while diversifying into complementary products;
o The Group is expanding its geographical footprint and developing a dual Rx/OTC commercial model to build on its strong brand recognition.
Research and Development
Ipsen’s R&D activities are focused on the discovery and development of new molecules and on programs to manage the lifecycle of our existing products, and to invest in new assets to become a leading global biotech company focused on innovation and specialty care.
Focused on peptides and toxins, our R&D teams are constantly deepening and adding to the expertise of these two platforms. Our goal is to improve understanding of both the basic science and clinical aspects of peptides and toxins. The company has currently a strong clinical development platform with two ongoing programs in Systemic Radiation therapy (SRT), within multiple solid tumors, as well as preclinical to clinical research ongoing on next generation botulinum toxins. Furthermore, multiple trials are ongoing evaluating the combination treatment of Cabozantinib and immune-oncology therapeutic targets, in several different solid tumor types, and also trials in the company’s most recent assets Palovarotene and BLU-782 in ultra-rare bone disorders
Furthermore, Ipsen has entered into agreements with highly specialized companies in these fields and is strengthening its partnership policy through agreements with major research institutes and medical centers of excellence, on a global scale.
Ipsen has three R&D centers located at the heart of three internationally renowned science hubs: Paris-Saclay in France, Oxford in the United Kingdom, and Cambridge in the United States. In close contact with leading academic research centers, cutting-edge medical centers and biotechnological companies, Ipsen has an active partnership policy based on open innovation.
For more information about Ipsen R&D and pipeline see appendix 1.
For further information about Ipsen, please visit http://www.ipsen.com and http://www.ipsennordic.com
Ipsen Nordics
In the Nordic countries, we are represented since 2006 with a Nordic office in Kista Science Tower outside Stockholm. In 2019, Ipsen was announced as the fastest growing pharma company in Sweden according to Läkemedelsmarknaden and had a net sale of about 60 million Euros in 2018, with a growth of 38% vs previous year.
In Norway, Denmark and Finland, we have locally based product specialists and medical representation. Today we are about 45 employees in the Nordic region who work within medical affairs, clinical research, market access, regulatory, finance, marketing and sales of our products. We work mainly in the therapeutic areas of endocrinology, oncology (renal cell carcinoma, hepatocellular carcinoma, prostate cancer), neuromuscular diseases, and ultra-rare bone disorders. We also have our Baltic marketing organization, with around 20 people, belonging to the cluster.
The Medical department Nordic and Baltics has about 10 employees with primary focus on medical affairs, clinical research and medical information. Medical is represented in all cross-functional brand teams and has a key role in the company’s business strategy.
Ipsen in Rare Diseases
At Ipsen, we’re driven to develop and enable timely access to innovate therapies and provide solutions for people living with debilitating and/or life-threatening rare conditions.
Working together with the rare disease community, we strive to better understand the challenges faced by patients and their families and then build on our expertise to address them.
The acquisition of Clementia Pharmaceuticals in April 2019, and Blueprint medicines in October 2019 demonstrates Ipsen’s ongoing commitment to and investment in rare diseases.
Through the recent acquisition of Clementia, we gained palovarotene (a RAR-γ agonist), a first-in-class asset which will enhance our ability to treat those affected by Fibrodysplasia Progressiva Ossificans (FOP) and multiple osteochondromas (MO). With the additional investment of BLU-782, an investigational ALK2 inhibitor from Blueprint medicines for the treatment of FOP, it is also a clear demonstration of our commitment to our growth strategy and building a leading Rare Diseases franchise. Both drugs are currently in phase 2 and phase 3 clinical trials.
Ipsen Group
Ipsen is a dynamic and growing global specialty-driven biopharmaceutical company focused on innovation and specialty care. We aim to make a sustainable difference by significantly improving patients’ health and quality of life and providing them with effective therapeutic solutions for unmet medical needs through differentiated and innovative medicines in oncology, neurosciences and rare diseases. The patient is at the heart of everything we do, and we also care for our employees because they are the ambassadors who truly make the difference. We attract and develop bold, agile, entrepreneurial individuals who take full ownership of their decisions; leaders drawn by a purpose to make a direct impact through their work in people’s lives. We offer employees a wealth of fulfilling challenges & growth opportunities, and the chance to contribute within a fast-moving organisation, an organisation that is genuinely game-changing.
Ipsen is a global specialty-driven pharmaceutical company and also has a significant presence in consumer healthcare. Ipsen commercialize more than 20 drugs in over 115 countries, with a direct commercial presence in 30 countries worldwide. The Group has about 5,800 employees worldwide. The company recorded a net sale of 2,224.8 million Euros 2018 and a growth of 16.6% vs previous year.
Our strategy
Ipsen’s strategy is based on a focus on niche therapeutic areas in specialty care and on gastroenterology in consumer healthcare.
• Specialty care:
o A focus on three niche therapeutic areas where Ipsen is committed to continue being or becoming leader in high unmet need disease areas of oncology, neurology and rare disease;
o Ipsen continues to strengthen its presence in its historical therapeutic specialty areas such as uro-oncology, neurospastic disorders and endocrinology
o At the same time, we are pursuing advancements in othertherapeutic areas within oncology and rare disease.
• Consumer healthcare:
o Ipsen aims to optimize its gastroenterology portfolio while diversifying into complementary products;
o The Group is expanding its geographical footprint and developing a dual Rx/OTC commercial model to build on its strong brand recognition.
Research and Development
Ipsen’s R&D activities are focused on the discovery and development of new molecules and on programs to manage the lifecycle of our existing products, and to invest in new assets to become a leading global biotech company focused on innovation and specialty care.
Focused on peptides and toxins, our R&D teams are constantly deepening and adding to the expertise of these two platforms. Our goal is to improve understanding of both the basic science and clinical aspects of peptides and toxins. The company has currently a strong clinical development platform with two ongoing programs in Systemic Radiation therapy (SRT), within multiple solid tumors, as well as preclinical to clinical research ongoing on next generation botulinum toxins. Furthermore, multiple trials are ongoing evaluating the combination treatment of Cabozantinib and immune-oncology therapeutic targets, in several different solid tumor types, and also trials in the company’s most recent assets Palovarotene and BLU-782 in ultra-rare bone disorders
Furthermore, Ipsen has entered into agreements with highly specialized companies in these fields and is strengthening its partnership policy through agreements with major research institutes and medical centers of excellence, on a global scale.
Ipsen has three R&D centers located at the heart of three internationally renowned science hubs: Paris-Saclay in France, Oxford in the United Kingdom, and Cambridge in the United States. In close contact with leading academic research centers, cutting-edge medical centers and biotechnological companies, Ipsen has an active partnership policy based on open innovation.
For more information about Ipsen R&D and pipeline see appendix 1.
For further information about Ipsen, please visit http://www.ipsen.com and http://www.ipsennordic.com
Ipsen Nordics
In the Nordic countries, we are represented since 2006 with a Nordic office in Kista Science Tower outside Stockholm. In 2019, Ipsen was announced as the fastest growing pharma company in Sweden according to Läkemedelsmarknaden and had a net sale of about 60 million Euros in 2018, with a growth of 38% vs previous year.
In Norway, Denmark and Finland, we have locally based product specialists and medical representation. Today we are about 45 employees in the Nordic region who work within medical affairs, clinical research, market access, regulatory, finance, marketing and sales of our products. We work mainly in the therapeutic areas of endocrinology, oncology (renal cell carcinoma, hepatocellular carcinoma, prostate cancer), neuromuscular diseases, and ultra-rare bone disorders. We also have our Baltic marketing organization, with around 20 people, belonging to the cluster.
The Medical department Nordic and Baltics has about 10 employees with primary focus on medical affairs, clinical research and medical information. Medical is represented in all cross-functional brand teams and has a key role in the company’s business strategy.
Ipsen in Rare Diseases
At Ipsen, we’re driven to develop and enable timely access to innovate therapies and provide solutions for people living with debilitating and/or life-threatening rare conditions.
Working together with the rare disease community, we strive to better understand the challenges faced by patients and their families and then build on our expertise to address them.
The acquisition of Clementia Pharmaceuticals in April 2019, and Blueprint medicines in October 2019 demonstrates Ipsen’s ongoing commitment to and investment in rare diseases.
Through the recent acquisition of Clementia, we gained palovarotene (a RAR-γ agonist), a first-in-class asset which will enhance our ability to treat those affected by Fibrodysplasia Progressiva Ossificans (FOP) and multiple osteochondromas (MO). With the additional investment of BLU-782, an investigational ALK2 inhibitor from Blueprint medicines for the treatment of FOP, it is also a clear demonstration of our commitment to our growth strategy and building a leading Rare Diseases franchise. Both drugs are currently in phase 2 and phase 3 clinical trials.
TILLSATT - Medical Affairs Rare diseases Nordics, Ipsen
Opportunity to develop a top notch product portfolio in a modern and innovtive company
The position Medical Affairs Rare diseases Nordics
Supervisor: Nordic & Baltic Medical Director
Department: Medical affairs department
Location: Sweden (Denmark) with responsibility for the Nordic (Sweden, Finland, Norway and Denmark)
“We attract and develop bold, agile, entrepreneurial individuals who take full ownership of their decisions; leaders drawn by a purpose to make a direct impact through their work in people’s lives. We offer employees a wealth of fulfilling challenges & growth opportunities, and the chance to contribute within a fast-moving organisation, an organisation that is genuinely game-changing”.
Purpose of the position
As a medical affairs Rare diseases, you will be responsible for the therapeutic area’s product portfolio. With your scientific expertise in those therapeutic area’s you are responsible for the roll-out of a successful medical strategy in close cooperation with marketing, market access and sales functions.
You make sure your medical plan is fully aligned with the Brand Strategy for the Rare diseases portfolio as a crucial member of the Brand Team.
You will be accountable for all medical activities related to the Rare diseases portfolio including but not limited to clinical trials, medical education meetings, advisory boards, scientific exchange meetings, and g medical information. You ensure all activities are in accordance with Ipsen SOPs and International Codes of Practice e.g. GCP, GPP and GPvP. You provide non-promotional, high level scientific, medical and technical support to Ipsen’s external (Health Care Professional) and internal stakeholders
Opportunities with the role
“We attract and develop bold, agile, entrepreneurial individuals who take full ownership of their decisions; leaders drawn by a purpose to make a direct impact through their work in people’s lives. We offer employees a wealth of fulfilling challenges & growth opportunities, and the chance to contribute within a fast-moving organisation, an organisation that is genuinely game-changing”.
• To represent Ipsen, a family owned fast growing global pharmaceutical company with a focus on R&D and a strong commitment to improve life for patients within Endocrinology, Oncology, Endocrinology and Rare Diseases
• Work in an innovative, expansive and dynamic company, deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses
• Take on a medical affairs role, having the opportunity to work with an attractive Rare diseases product portfolio adding value for healthcare and patient with different Rare disease diagnosis
• Having the possibility to implement new ideas and projects with influence of company development
• Be part of a Nordic team, with deep knowledge, highly motivated, and with a good cooperation and positive atmosphere
• Ipsen has an attractive company culture with excellent opportunities for professional and personal development (for instance very good opportunities for internal job rotation and career development globally)
Experience, qualifications and competencies
Required experience, skills and qualifications
• M.D. (medical degree) preferable specialized in oncology, endocrinology, gastroenterology, haematology or Rare Diseases with an experience from medical affairs in the pharmaceutical industry or a M.D. with relevant clinical/research experience with the motivation and talent to take on a Medical Advisor assignment at Ipsen
Or alternatively;
• Science degree preferable specialized in oncology, endocrinology, gastroenterology, haematology or Rare Diseases with an experience from medical affairs in the pharmaceutical industry or a Science degree with relevant clinical/research experience with the motivation and talent to take on a Medical Advisor assignment at Ipsen
• Preferably scientific research degree or experience
• A solid experience from medical affairs in the pharmaceutical industry or alternatively a relevant clinical/research experience with a motivation and talent to take on a Medical Advisor assignment at Ipsen
• Preferably experience in post-marketing clinical research, and observational studies or real-world data and patient registry analysis.
• Good understanding and interest in business conduct
• An understanding of the drug development process and a good knowledge of the therapeutic area would be a strong advantage
• Knowledge of local regulatory rules and guidelines
• Knowledge of, and current training in, GxP (GCP, GPvP, and other applicable instruments and regulations governing clinical research, medical information and scientific communication
• Proven experience of critically appraising clinical evidence, and an ability to assimilate large volumes of data.
• Languages: Expert/fluent communicator in Swedish and excellent knowledge of written and spoken scientific English
• Oncology experience and proven established relationships with the oncology field is an advantage
Key Competencies and behaviours
• Strong leadership, communication and influencing skills and commitment to compliance with the ethical and regulatory requirements accordingly health authorities and Ipsen processes and regulations
• Strong ability to build relationships, and high presentation and public speaking skills
• Strategic thinking (e.g. understand TL needs, identify issues and opportunities, develop targeted multifaceted solutions). Have a helicopter view.
• Produces new ideas and challenge the convention, creating innovation and development
• Strong analytical and numerical skills and an ability to execute plans and achieve outcomes in accordance with launch requirements and deadlines
• Demonstrated capacity to build strong relationships across functions and to work closely with all people across the business.
Other useful information
• Specifics of the position: The position is field-based and regular travel will be required within an assigned geography (the Nordics) as well as regular meetings at head office (in Sweden).
• The position is part of a European Business unit: regular travel will be required in Europe for internal and external meetings.
• Internal and external contacts (organisation): Cross-functional team members including field-based counterparts and internal stakeholders. Key Opinion Leaders, payers, formulary decision makers, and other healthcare providers and vendors, as appropriate.
Contact
For inquires, additional information and interest in the Medical Affairs Rare diseases Nordics position, please contact Magnus Klingberg, Senior Recruitment Consultant or Jenny Ringh, Senior Recruitment Consultant at PeakSearch.
Apply for the position at http://www.peaksearch.se.
Contact details
Magnus Klingberg
e-mail: magnus.klingberg@peaksearch.se
mobile: +46 (0)70-678 09 92 office telephone: +46 (0)8-545 00 100
Jenny Ringh
Email: jenny@peaksearch.se
Mobile: +46-(0)70-235 81 99, telephone: +46-(0)8-545 00 100
webb: http://www.peaksearch.se
Supervisor: Nordic & Baltic Medical Director
Department: Medical affairs department
Location: Sweden (Denmark) with responsibility for the Nordic (Sweden, Finland, Norway and Denmark)
“We attract and develop bold, agile, entrepreneurial individuals who take full ownership of their decisions; leaders drawn by a purpose to make a direct impact through their work in people’s lives. We offer employees a wealth of fulfilling challenges & growth opportunities, and the chance to contribute within a fast-moving organisation, an organisation that is genuinely game-changing”.
Purpose of the position
As a medical affairs Rare diseases, you will be responsible for the therapeutic area’s product portfolio. With your scientific expertise in those therapeutic area’s you are responsible for the roll-out of a successful medical strategy in close cooperation with marketing, market access and sales functions.
You make sure your medical plan is fully aligned with the Brand Strategy for the Rare diseases portfolio as a crucial member of the Brand Team.
You will be accountable for all medical activities related to the Rare diseases portfolio including but not limited to clinical trials, medical education meetings, advisory boards, scientific exchange meetings, and g medical information. You ensure all activities are in accordance with Ipsen SOPs and International Codes of Practice e.g. GCP, GPP and GPvP. You provide non-promotional, high level scientific, medical and technical support to Ipsen’s external (Health Care Professional) and internal stakeholders
Opportunities with the role
“We attract and develop bold, agile, entrepreneurial individuals who take full ownership of their decisions; leaders drawn by a purpose to make a direct impact through their work in people’s lives. We offer employees a wealth of fulfilling challenges & growth opportunities, and the chance to contribute within a fast-moving organisation, an organisation that is genuinely game-changing”.
• To represent Ipsen, a family owned fast growing global pharmaceutical company with a focus on R&D and a strong commitment to improve life for patients within Endocrinology, Oncology, Endocrinology and Rare Diseases
• Work in an innovative, expansive and dynamic company, deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses
• Take on a medical affairs role, having the opportunity to work with an attractive Rare diseases product portfolio adding value for healthcare and patient with different Rare disease diagnosis
• Having the possibility to implement new ideas and projects with influence of company development
• Be part of a Nordic team, with deep knowledge, highly motivated, and with a good cooperation and positive atmosphere
• Ipsen has an attractive company culture with excellent opportunities for professional and personal development (for instance very good opportunities for internal job rotation and career development globally)
Experience, qualifications and competencies
Required experience, skills and qualifications
• M.D. (medical degree) preferable specialized in oncology, endocrinology, gastroenterology, haematology or Rare Diseases with an experience from medical affairs in the pharmaceutical industry or a M.D. with relevant clinical/research experience with the motivation and talent to take on a Medical Advisor assignment at Ipsen
Or alternatively;
• Science degree preferable specialized in oncology, endocrinology, gastroenterology, haematology or Rare Diseases with an experience from medical affairs in the pharmaceutical industry or a Science degree with relevant clinical/research experience with the motivation and talent to take on a Medical Advisor assignment at Ipsen
• Preferably scientific research degree or experience
• A solid experience from medical affairs in the pharmaceutical industry or alternatively a relevant clinical/research experience with a motivation and talent to take on a Medical Advisor assignment at Ipsen
• Preferably experience in post-marketing clinical research, and observational studies or real-world data and patient registry analysis.
• Good understanding and interest in business conduct
• An understanding of the drug development process and a good knowledge of the therapeutic area would be a strong advantage
• Knowledge of local regulatory rules and guidelines
• Knowledge of, and current training in, GxP (GCP, GPvP, and other applicable instruments and regulations governing clinical research, medical information and scientific communication
• Proven experience of critically appraising clinical evidence, and an ability to assimilate large volumes of data.
• Languages: Expert/fluent communicator in Swedish and excellent knowledge of written and spoken scientific English
• Oncology experience and proven established relationships with the oncology field is an advantage
Key Competencies and behaviours
• Strong leadership, communication and influencing skills and commitment to compliance with the ethical and regulatory requirements accordingly health authorities and Ipsen processes and regulations
• Strong ability to build relationships, and high presentation and public speaking skills
• Strategic thinking (e.g. understand TL needs, identify issues and opportunities, develop targeted multifaceted solutions). Have a helicopter view.
• Produces new ideas and challenge the convention, creating innovation and development
• Strong analytical and numerical skills and an ability to execute plans and achieve outcomes in accordance with launch requirements and deadlines
• Demonstrated capacity to build strong relationships across functions and to work closely with all people across the business.
Other useful information
• Specifics of the position: The position is field-based and regular travel will be required within an assigned geography (the Nordics) as well as regular meetings at head office (in Sweden).
• The position is part of a European Business unit: regular travel will be required in Europe for internal and external meetings.
• Internal and external contacts (organisation): Cross-functional team members including field-based counterparts and internal stakeholders. Key Opinion Leaders, payers, formulary decision makers, and other healthcare providers and vendors, as appropriate.
Contact
For inquires, additional information and interest in the Medical Affairs Rare diseases Nordics position, please contact Magnus Klingberg, Senior Recruitment Consultant or Jenny Ringh, Senior Recruitment Consultant at PeakSearch.
Apply for the position at http://www.peaksearch.se.
Contact details
Magnus Klingberg
e-mail: magnus.klingberg@peaksearch.se
mobile: +46 (0)70-678 09 92 office telephone: +46 (0)8-545 00 100
Jenny Ringh
Email: jenny@peaksearch.se
Mobile: +46-(0)70-235 81 99, telephone: +46-(0)8-545 00 100
webb: http://www.peaksearch.se